Scarica l'app Stockscreener
44.44
0.05%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$44.40
Aprire:
$44.2
Volume 24 ore:
946.59K
Relative Volume:
0.36
Capitalizzazione di mercato:
$11.91B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
25.10
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
+0.56%
1M Prestazione:
+10.03%
6M Prestazione:
+4.83%
1 anno Prestazione:
+23.25%
Intervallo 1D:
$43.85
$44.59
Intervallo di 1 settimana:
$43.00
$44.79
Portata 52W:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.44 | 11.90B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.95 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.72 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.07 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.80 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.99 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Will Exelixis Inc. (EX9) stock outperform energy sector in 20252025 Trading Recap & Low Risk High Win Rate Picks - Newser
Will Exelixis Inc. stock attract more institutional investorsTrend Reversal & Reliable Entry Point Trade Alerts - Newser
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
How forex fluctuations impact Exelixis Inc. (EX9) stockRisk Management & Weekly Stock Performance Updates - Newser
Will Exelixis Inc. (EX9) stock profit from automation wave2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
Why Exelixis Inc. (EX9) stock appeals to dividend investorsTreasury Yields & AI Forecasted Stock Moves - Newser
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? - Yahoo Finance
Will Exelixis Inc. (EX9) stock rise with strong economyWeekly Stock Summary & Smart Money Movement Alerts - Newser
How Exelixis Inc. (EX9) stock compares with top peers2025 Market Overview & Safe Entry Momentum Stock Tips - Newser
Can Exelixis Inc. (EX9) stock beat analyst consensusWeekly Profit Analysis & Reliable Breakout Stock Forecasts - Newser
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
Exelixis (NASDAQ:EXEL) shareholders have earned a 39% CAGR over the last three years - Yahoo Finance
Vascular Endothelial Growth Factor Receptor (VEGFR) - openPR.com
Is Exelixis Inc. stock a buy for dividend growthWall Street Watch & Free Community Supported Trade Ideas - Newser
How Exelixis Inc. (EX9) stock trades under stagflationQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Will Exelixis Inc. (EX9) stock announce a stock split2025 Earnings Impact & Weekly Top Gainers Trade List - Newser
Can Exelixis Inc. (EX9) stock retain market dominanceRate Cut & Daily Risk Controlled Trade Plans - Newser
2 Under-the-Radar Stocks to Buy Heading Into 2026 - Finviz
2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
EXEL (Exelixis) Earnings Yield (Joel Greenblatt) % : 7.99% (As of Sep. 2025) - GuruFocus
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK
Here's Why Exelixis (EXEL) is a Strong Growth Stock - MSN
EXEL (Exelixis) Cash, Cash Equivalents, Marketable Securities : $989 Mil (As of Sep. 2025) - GuruFocus
EXEL (Exelixis) Total Assets : $2,824 Mil (As of Sep. 2025) - GuruFocus
Hedge Fund and Insider Trading News: Ray Dalio, Michael Burry, Marshall Wace, Exelixis Inc (EXEL), Monolithic Power Systems Inc (MPWR), and More - Insider Monkey
Exelixis (LTS:0IJO) FCF Yield % : 6.28 (As of Nov. 28, 2025) - GuruFocus
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners - MSN
How (EXEL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Exelixis Inc Stock Analysis and ForecastProtective Put Strategies & Budget Friendly Trading Strategies - earlytimes.in
Aug Rallies: How Exelixis Inc. stock reacts to job market dataQuarterly Market Review & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Exelixis (EXEL) Director Invests $1.2 Million in Company Stock - GuruFocus
Dir Johnson Buys 27,532 ($1.2M) Of Exelixis Inc [EXEL] - TradingView
Caligan-linked Exelixis director reports 27,532-share EXEL purchase - Stock Titan
Exelixis, Inc.Common Stock (NQ: EXEL - Markets Financial Content
Exelixis EVP Haley sells shares worth $3m By Investing.com - Investing.com South Africa
Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing - marketscreener.com
EDGAR Filing Documents for 0000939767-25-000127 - SEC.gov
EXEL insider Form 4: EVP gifts 24,000 Exelixis shares - Stock Titan
Exelixis EVP Haley sells shares worth $3m - Investing.com
VP Aftab Gifts 24,000 Of Exelixis Inc [EXEL] - TradingView
Exelixis EVP Patrick J. Haley Sells Over $3 Million in Company Stock - TradingView
EXELIXIS INC (1EXEL.MI) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Exelixis Is Focusing On Neuroendocrine Tumors — But Is a $100 Million Windfall Next? - Smartkarma
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - MSN
[Form 3] EXELIXIS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Why Exelixis Inc. stock attracts high net worth investorsQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exelixis Inc Azioni (EXEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Haley Patrick J. | EVP, Commercial |
Nov 20 '25 |
Sale |
41.88 |
34,187 |
1,431,757 |
0 |
| Haley Patrick J. | EVP, Commercial |
Nov 21 '25 |
Sale |
42.58 |
28,043 |
1,194,071 |
374,029 |
| Haley Patrick J. | EVP, Commercial |
Nov 20 '25 |
Sale |
42.11 |
10,000 |
421,100 |
402,072 |
0.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):